Literature DB >> 16129800

Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart.

Denise Hilfiker-Kleiner1, Andres Hilfiker, Karol Kaminski, Arnd Schaefer, Joon-Keun Park, Kim Michel, Anja Quint, Moshe Yaniv, Jonathan B Weitzman, Helmut Drexler.   

Abstract

BACKGROUND: The Jun family of activator protein 1 (AP-1) transcription factors (c-Jun, JunB, and JunD) is involved in fundamental biological processes such as proliferation, apoptosis, tumor angiogenesis, and hypertrophy. The role of individual AP-1 transcription factors in the stressed heart is not clear. In the present study we analyzed the role of JunD in survival, hypertrophy, and angiogenesis in the pressure-overloaded mouse heart after thoracic aortic constriction. METHODS AND
RESULTS: Mice lacking JunD (knockout [KO]) showed increased mortality and enhanced cardiomyocyte apoptosis and fibrosis associated with increased levels of hypoxia-induced factor-1alpha, vascular endothelial growth factor (VEGF), p53, and Bax protein and reduced levels of Bcl-2 protein after 7 days of severe pressure overload compared with wild-type (WT) siblings. Cardiomyocyte hypertrophy in surviving KO mice was enhanced compared with that in WT mice. Chronic moderate pressure overload for 12 weeks caused enhanced left ventricular hypertrophy in KO mice, and survival and interstitial fibrosis were comparable with WT mice. Cardiac function, 12 weeks after operation, was comparable among shams and pressure-overloaded mice of both genotypes. In addition, KO mice exposed to chronic pressure overload showed higher cardiac capillary density associated with increased protein levels of VEGF.
CONCLUSIONS: Thus, JunD limits cardiomyocyte hypertrophy and protects the pressure-overloaded heart from cardiac apoptosis. These beneficial effects of JunD, however, are associated with antiangiogenic properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129800     DOI: 10.1161/CIRCULATIONAHA.104.518472

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation.

Authors:  Mark Y Jeong; John S Walker; R Dale Brown; Russell L Moore; Charles S Vinson; Wilson S Colucci; Carlin S Long
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

Review 3.  Ageing, metabolism and cardiovascular disease.

Authors:  Sarah Costantino; Francesco Paneni; Francesco Cosentino
Journal:  J Physiol       Date:  2015-10-22       Impact factor: 5.182

4.  Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload.

Authors:  Yasuhiro Izumiya; Ichiro Shiojima; Kaori Sato; Douglas B Sawyer; Wilson S Colucci; Kenneth Walsh
Journal:  Hypertension       Date:  2006-03-27       Impact factor: 10.190

Review 5.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

6.  Angiotensin II signaling up-regulates the immediate early transcription factor ATF3 in the left but not the right atrium.

Authors:  Tal Hasin; Ofer Elhanani; Zaid Abassi; Tsonwin Hai; Ami Aronheim
Journal:  Basic Res Cardiol       Date:  2010-12-30       Impact factor: 17.165

Review 7.  Vascular endothelial growth factor in heart failure.

Authors:  Ziad Taimeh; John Loughran; Emma J Birks; Roberto Bolli
Journal:  Nat Rev Cardiol       Date:  2013-07-16       Impact factor: 32.419

8.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases.

Authors:  Alexa Klettner; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-15       Impact factor: 3.117

9.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

Review 10.  Multiple facets of junD gene expression are atypical among AP-1 family members.

Authors:  J M Hernandez; D H Floyd; K N Weilbaecher; P L Green; K Boris-Lawrie
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.